The present invention relates to improving the processing rate of a sequencing reaction, for example in a nanopore sequencing reaction, by means of using improved nucleoside-tags. The tags are linked to the nucleoside phosphate via a Pictet Spengler reaction. Exemplary sequencing reactions that are improved by the present methods include nanopore-based nucleic acid sequencing-by-synthesis reactions.

The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted with a monovalent group comprising either (i) an aryl or a heteroaryl group, or (ii) a nitrogen-containing heterocyclic group, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted at the 2- and 4-positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP.sub.3inhibition.

##STR00001##

The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted with a monovalent group comprising either (i) an aryl or a heteroaryl group, or (ii) a nitrogen-containing heterocyclic group, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted at the 2- and 4-positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP.sub.3inhibition.

##STR00001##

Provided is a CCR2/CCR5 receptor antagonist and the use thereof in the preparation of a drug for treating diseases associated with the CCR2/CCR5. In particular, disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. ##STR00001##

Provided is a CCR2/CCR5 receptor antagonist and the use thereof in the preparation of a drug for treating diseases associated with the CCR2/CCR5. In particular, disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. ##STR00001##

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

A compound represented by formula (I) ##STR00001## or an N-oxide compound thereof is provided with excellent control efficacies against harmful arthropods, wherein A.sup.1 represents a nitrogen atom or a CR.sup.4; R.sup.4 represents a hydrogen atom, a OR.sup.27, a NR.sup.27R.sup.28, a cyano group, a nitro group, or a halogen atom; ##STR00002##
hereinafter referred to as “Het”, represents Het-1, Het-2, Het-3, or Het-4: ##STR00003## wherein #.sup.1 represents the binding position of Het and T, and #.sup.2 represents the binding position of Het and ##STR00004## T represents T-1, T-2, T-3, T-4, T-5, T-6, or T-7: ##STR00005## R.sup.1 represents a C1-C10 chain hydrocarbon group having one or more halogen atoms or the like; and R.sup.2 represents a C1-C6 alkyl group optionally having one or more halogen atoms or the like.

A compound represented by formula (I) ##STR00001## or an N-oxide compound thereof is provided with excellent control efficacies against harmful arthropods, wherein A.sup.1 represents a nitrogen atom or a CR.sup.4; R.sup.4 represents a hydrogen atom, a OR.sup.27, a NR.sup.27R.sup.28, a cyano group, a nitro group, or a halogen atom; ##STR00002##
hereinafter referred to as “Het”, represents Het-1, Het-2, Het-3, or Het-4: ##STR00003## wherein #.sup.1 represents the binding position of Het and T, and #.sup.2 represents the binding position of Het and ##STR00004## T represents T-1, T-2, T-3, T-4, T-5, T-6, or T-7: ##STR00005## R.sup.1 represents a C1-C10 chain hydrocarbon group having one or more halogen atoms or the like; and R.sup.2 represents a C1-C6 alkyl group optionally having one or more halogen atoms or the like.

The present disclosure provides processes for the synthesis of organic compounds, in particular processes for the synthesis of heteroaryl-substituted sulfur(VI) compounds by nucleophilic aromatic substitution.